ProtoKinetix FY25 net loss widens to $393,650; revenue remains no revenue
PKTX•Cash position and funding plan
Year-end cash totaled $1,118 and working capital deficit widened to $183,266.
The company said it plans to fund operations through common-stock sales.
Fiscal 2025 results and expenses
ProtoKinetix posted a net loss of $393,650 in fiscal 2025, widening 8.09% from the prior year.
- No revenue was recorded, leaving operating loss at $393,650 versus 2024.
- Professional fees climbed 22.66% to $177,610, driven by legal work on authorized-share voting and a patent-portfolio valuation report.
- Research and development spending rose 7.01% to $106,613 on higher molecule-inventory storage fees.
